导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.84% | 2745/4744 |
| 近一周 | -2.18% | 1398/5430 |
| 近一月 | -4.15% | 2241/5389 |
| 近一季 | -7.46% | 2386/5179 |
| 近半年 | -2.77% | 2002/4890 |
| 近一年 | 0.63% | 2504/4340 |
| 近两年 | 44.25% | 1671/2945 |
| 近三年 | 26.87% | 1186/2246 |
| 成立以来 | 39.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.54% 3273/4961 |
12.14% 2221/5312 |
- - |
- - |
| 2025 | 19.53% 2209/4813 |
-0.99% 2517/3635 |
2.16% 1799/4076 |
17.96% 2385/4524 |
0.17% 2158/4813 |
| 2024 | 16.16% 842/3463 |
2.78% 703/2808 |
-1.11% 938/3014 |
16.16% 1518/3129 |
-1.62% 1773/3463 |
| 2023 | -8.87% 1069/2656 |
4.32% 982/2280 |
-3.84% 925/2385 |
-2.89% 783/2515 |
-6.45% 1781/2655 |
| 2022 | -19.12% 802/2207 |
-13.81% 846/1919 |
6.63% 646/2016 |
-13.60% 929/2113 |
1.86% 1115/2208 |
| 2021 | -2.62% 863/1822 |
-2.93% 730/1255 |
4.36% 896/1330 |
-5.40% 802/1466 |
1.62% 860/1822 |
| 2020 | 29.45% 538/1250 |
-9.27% 666/1028 |
13.26% 632/1067 |
11.34% 460/1164 |
13.14% 389/1184 |
| 2019 | - - |
- - |
- - |
0.65% 493/850 |
6.81% 543/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达沪深300ETF联接C VS. 长安沪深300非周期A(740101) |